KTX 582
Alternative Names: KTX-582Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Kymera Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Interleukin-1 receptor-associated kinase degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA
- 10 Dec 2022 Pharmacodynamics data from a preclinical trial in Diffuse large B cell lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 07 Dec 2020 Pharmacodynamics data from a preclinical trial in diffuse large B cell lymphoma released by Kymera Therapeutics